The Food and Drug Administration (FDA) recently approved the application of TRIESENCE to move on to phase 3 clinical trial to continue to evaluate it's safety and efficacy in treating ocular inflammation and pain after cataract surgery.
TRIESENCE is already approved for a wide range of intraocular uses for the treatment of inflammation. It is a preservative-free triamcinolone acetonide injectable suspension.
Harrow, the manufacturer of TRIESENCE, hopes to expand the on-label usage of TRIESENCE for all cataract surgery patients. Approval of the drug for cataract surgery would reduce the need for patients to self-administer eye drops at home over a period of weeks.
Enrollment for the trial is expected in the second quarter of 2026 and will involved about 250 patients. The trial will last for around 120 days with the last visit being on day 90.
